Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis-Reference-Cited by-同舟云学术

Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis

Published:2021-07-31 Issue:8 Volume:41 Page:711-721
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Schilling Uta,Henrich Andrea,Muehlan Clemens,Krause Andreas,Dingemanse Jasper^ORCID,Ufer Mike

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-021-01062-1.pdf

Reference37 articles.

1. Reynolds CF, O’Hara R. DSM-5 sleep-wake disorders classification: overview for use in clinical practice. Am J Psychiatry. 2013;170(10):1099–101.

2. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7-10.

3. Krystal AD, Prather AA, Ashbrook LH. The assessment and management of insomnia: an update. World Psychiatry. 2019;18(3):337–52.

4. Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res. 2019;28(2):12782.

5. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8(3):171–81.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical safety of daridorexant in insomnia treatment: Analysis of FDA adverse event reports;Journal of Affective Disorders;2024-10

2. Daridorexant for patients with chronic insomnia disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed;Postgraduate Medicine;2024-05-18

3. New pharmaceuticals in the treatment of insomnia;Psychiatrie pro praxi;2023-10-16

4. Daridorexant as a novel pharmacotherapeutic approach in insomnia: a systematic review and meta-analysis;Expert Opinion on Drug Safety;2023-08-07

5. Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a₁ receptor) antagonist;Pharmacology Research & Perspectives;2023-07-20